Business Wire

NY-ALVAREZ-&-MARSAL

18.1.2023 07:01:35 CET | Business Wire | Press release

Share
Alvarez & Marsal Announces 2023 Managing Director Promotions

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.

Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”

Asia

Henry Chambers, Hong Kong

Eden Chen, Shanghai

Sally Sun, Hong Kong

Brazil

Pedro Bortolotto, São Paulo

Marcelo Compte, São Paulo

Rodrigo Domingues, São Paulo

Lilian Giorgi, São Paulo

Rodrigo Hong, São Paulo

Henrique Kanashiro, São Paulo

Rafael Mendonca Rodrigues, São Paulo

Fabio Missiato, São Paulo

Corporate Performance Improvement

Tiffany Guthrie, Houston

Mike Hall, San Francisco

John McKinnis, Dallas

Sam Rudkin, Atlanta

Consumer and Retail Group

Kenneth Cochran, Charlotte

Jeffrey Dwyer, Chicago

Lakshman Lakshmanan, Dallas

Chad Lusk, Chicago

Joanna Rangarajan, New York

Global Disputes and Investigations

Lee Betteridge, London

Gary Foster, London

EMEA – Performance Improvement

Private Equity Performance Improvement

Nicola Barbini, London

Chris Gobby, London

Britta Mittler, Frankfurt

Till Prinz, Dusseldorf

Tim Veen, Munich

Gerardo Villalba Bello, Madrid

Ysabel Gaspar Zayco, London

Financial Services Industry

Robert Bradbury, London

Dominic Roope, London

Corporate Transformation

Jatin Arora, Dubai

Mark Bennett, Paris

Daran Hopper, London

Dirk Naujokat, Munich

Steve Trainor, London

Diana Wong, London

EMEA Restructuring

Insolvency

Barry Lynch, Grand Cayman

Helen Skeates, London

Turnaround

David Johnston, London

José Miguel Gómez Rivas, Madrid

Middle East

Bill Ozturk, Dubai

Environmental, Social and Governance (ESG)

Stephanie Weiler, Chicago

Healthcare Industry Group

JoyAnn Book, Phoenix

Bianca A. Briola Charlotte

David Nidetz, Detroit

Rich Rieger, Chicago

India

Anup Gandhi, Mumbai

Pranav Sheth, Mumbai

Infrastructure & Capital Projects

Sue Frost, Washington, D.C.

Alan Richard, Washington, D.C.

Private Equity Performance Group

Kent Edgerton, Nashville

Jana Gold, Washington, D.C.

Brad Howard, New York

Larry Thomas, Tampa

Klaus Weisenberger, San Francisco

Public Sector

Daniel Harlan, Washington, D.C

Restructuring & Turnaround (North America)

Taylor Atwood, Dallas

Matthew Davidson, Detroit

Chad Ellison, Calgary

Kamila Khairoullina, New York

Mark Sidorenkov, Phoenix

Jeff Sielinski, Detroit

Michael Zembillas, Atlanta

Global Taxand

Simon Bernstein, New York

Stephanie Doughty, Houston

Michael Farkas, New York

Simon Gore, London

Jack Hollyman, London

Jac Emilio Martinez, Miami

Joseph Plati, New York

Brendan Sinnott, New York

Katya Umanskaya, Los Angeles

Global Transaction Advisory Group

Anuj Astir, New York

Nout Brugman, Amsterdam

David Cho, Chicago

Vitor Garcia, Sao Paulo

Jimmy Glenn, Atlanta

Nick Lynch, London

Jai Tandan, Mumbai

Rhett Taylor, Nashville

Nick Thoele, New York

Cedric Zana, Paris

Valuation Services

Cole Corbin, New York

Steven Fischoff, Chicago

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.

With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.

To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye